Todd Prickett

Staff Scientist

National Institutes of Health
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

PIK3CA is the third most common mutated gene in epithelial cancers, behind only TP53 and KRAS . Somatic PIK3CA mutations occur predominantly in the protein’s hotspot locations H1047, E545, E542 and N345, and evidence of those alterations eliciting immune responses has been limited. HLA class I-restricted TCRs against E545K and H1047L have, only recently, been identified following in vitro sensitization (IVS) with peripheral blood lymphocytes (PBL) from normal donors. In this study, we examined the immunogenicity of PIK3CA in patients with epithelial cancers of diverse histology, by testing TIL and antigen-experienced PBL against autologous hotspot PIK3CA mutations. Two distinct TCRs specific to PIK3CA N345K , restricted by HLA-class II pair DPB1*04:01/DPA1*01:03, were identified in a patient with colon cancer, following independently a TIL screen and an IVS of memory CD4 + T cells from the peripheral blood. Patient PBL engineered to express each TCR suppressed the in vitro growth of two cell lines modified to express the DPB1*04:01/DPA1*01:03 pair and full length PIK3CA N345K protein. A TCR specific to the PIK3CA E545K , restricted by HLA-DRB1*04:01, was also identified following IVS of memory CD4 + PBL from another patient, with rectal cancer. Autologous PBL, gene engineered to express the PIK3CA E545K -specific TCR, suppressed the in vitro growth of two cancer cell lines, which endogenously expressed the PIK3CA E545K neoantigen. This study identified three PIK3CA-specific TCRs against two shared mutations, restricted by common HLA-class II molecules, using antigen-experienced TIL and memory PBL from patients with epithelial cancers and may further allow the development of off-the-shelf T cell immunotherapy strategies targeting PIK3CA.

Year:

2025

Extent of IMPACT CpG island promoter methylation in mouse cell lines (KPC, 4964-POP, and 4964-HOP), and five human pancreatic liver metastases compared to three primary PDACs, and two normal pancreas and liver tissue.

Year:

2025

List of all hits identified in the cDNA screen and categorized by function. cDNAs highlighted in red were identified in the 3 KB library fraction. The number of tumor lesions identifying the cDNA is given.

Year:

2025

Given the propensity of aggressive epithelial tumors to form hepatic metastases, we performed an in vivo cDNA screen using the mouse liver and KRAS G12D / TP53 R273H pancreatic cells that identified the RNA-binding protein GCN1 as an integral component of hepatic outgrowth. RNAi experiments reveal that GCN1 triggers the integrated stress response (ISR) to activate serine, folate, and methionine biosynthetic pathways together with amino acid transporters, which act in concert to facilitate acquisition of metabolites and to restore redox homeostasis. Alongside the activation of the ISR, we found that GCN1 also functions in the nucleus where it interacts with HNRNPK to suppress the expression of MHC-I molecules and NK ligands. Intriguingly, we identified IMPACT as an endogenous competitive inhibitor of GCN1 that blocks both ISR-dependent metabolic control and disrupts HNRNPK interaction. In doing so, IMPACT enhances tumor immunogenicity to unleash NK cell killing, in addition to sensitizing metastatic tumor cells to immune checkpoint blockade. Significance: Metastatic tumor cells display profound immunometabolic plasticity to colonize distant organs. We identify IMPACT, an inhibitor of GCN1-stress signaling, expression of which curtailed metabolic plasticity and augmented tumor immunogenicity, sensitizing metastatic tumor cells to NK cell–mediated destruction.

Year:

2025

Collaborators (12)

Pankaj Singh

Professor and Chair

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Kirsten Remmert

Staff Scientist

National Institutes of Health

UNITED STATES
View details

Marina Pasca Di Magliano

Associate Professor

University of Michigan

UNITED STATES
View details

Alexander Rossi

Assistant Professor

Yale University

UNITED STATES
View details

Margaret Cam

Staff Scientist

National Institutes of Health

UNITED STATES
View details

Rodrigo Xavier das Neves

Research Assistant Professor

University of Pittsburgh

UNITED STATES
View details

James Yang

National Cancer Institute

UNITED STATES
View details

Carolina Larrain

NYU Langone Health

UNITED STATES
View details

Reed Ayabe

Assistant Professor

University of California Irvine Medical Center

UNITED STATES
View details

Jeremy Davis

Professor and Chief, Division of Surgical Oncology

University of Maryland School of Medicine

UNITED STATES
View details

Costas A. Lyssiotis

University of Michigan

UNITED STATES
View details

sivasish sindiri

National Cancer Institute

UNITED STATES
View details